Skip to main content
. Author manuscript; available in PMC: 2011 Aug 27.
Published in final edited form as: Mol Cell. 2010 Aug 27;39(4):493–506. doi: 10.1016/j.molcel.2010.07.023

Figure 6. MiR-181b-1 regulates CYLD expression during ER-Src transformation.

Figure 6

(A) Sequence complementarity between miR-181b-1 and the 3’UTR of CYLD gene. (B) MiR-181b-1 and CYLD mRNA expression levels at the indicated times during ER-Src transformation. (C) Luciferase activity of a reporter containing the 3’UTR of CYLD 24h after transfection with miR-181b-1 or miR negative control. (D) CYLD mRNA levels after treatment with miR-181b-1 or miR negative control. (E) CYLD protein levels after treatment with miR-181b-1 or miR negative control. (F) CYLD mRNA levels after treatment with as-miR-181b-1 or as-miR-NC. (G) NF-κB activity (ELISA assay) in ER-Src cells untreated (NT) or treated with as-miR-181b-1, si-CYLD, or as-miR-NC. (H) IL6 production (ELISA assay) in ER-Src cells treated with as-miR-181b-1, si-CYLD or as-miR-NC. (I) Number of colonies, (J) NF-κB activity assessed by ELISA assay and (K) IL6 luciferase activity in ER-Src cells treated with two different siRNAs against CYLD. The data are presented as mean ± SD of three independent experiments.